Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA.

Am J Hematol. 2020 Mar 4. doi: 10.1002/ajh.25777. [Epub ahead of print]

PMID:
32129512
2.

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S.

Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23.

PMID:
31982039
3.

Phenotypic Characterization of Rhodococcus equi Biofilm Grown In Vitro and Inhibiting and Dissolving Activity of Azithromycin/Rifampicin Treatment.

Rampacci E, Marenzoni ML, Giovagnoli S, Passamonti F, Coletti M, Pietrella D.

Pathogens. 2019 Dec 4;8(4). pii: E284. doi: 10.3390/pathogens8040284.

4.

Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia.

Merli M, Bianchi B, Bertù L, Ferrario A, Mora B, Furlan D, Uccella S, Sessa F, Passamonti F.

Leuk Lymphoma. 2020 Apr;61(4):987-989. doi: 10.1080/10428194.2019.1689393. Epub 2019 Nov 14. No abstract available.

PMID:
31724890
5.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F.

Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. No abstract available.

6.

Analysis of three screening methods for the detection of calreticulin gene mutations.

Accetta R, Elli L, Libera L, Siracusa C, Cassavia F, Orsini F, Orlandi L, Passamonti F, Casalone R, Pallotti F.

Int J Lab Hematol. 2020 Apr;42(2):e76-e79. doi: 10.1111/ijlh.13117. Epub 2019 Nov 6. No abstract available.

PMID:
31693300
7.

Standard care and investigational drugs in the treatment of myelofibrosis.

Barraco D, Maffioli M, Passamonti F.

Drugs Context. 2019 Sep 26;8:212603. doi: 10.7573/dic.212603. eCollection 2019. Review.

8.

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

Merli M, Passamonti F.

Am J Hematol. 2019 Dec;94(12):1303-1305. doi: 10.1002/ajh.25662. Epub 2019 Nov 7. No abstract available.

PMID:
31621103
9.

In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.

Baccarani M, Iacobucci I, Chiaretti S, Foà' R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, Coriu D, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Poopak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibali O, Crugnola M, Passamonti F.

Leukemia. 2020 Mar;34(3):929-931. doi: 10.1038/s41375-019-0591-9. Epub 2019 Oct 8. No abstract available.

PMID:
31595038
10.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1. No abstract available.

PMID:
31588594
11.

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.

Visco C, Rodeghiero F, Romano A, Valeri F, Merli M, Quaresimini G, Volpetti S, Santi RM, Carli G, Lucchini E, Passamonti F, Rambaldi A, Motta G, Borchiellini A, d'Amore ESG, Ruggeri M.

Blood. 2019 Nov 14;134(20):1708-1711. doi: 10.1182/blood.2019001617.

PMID:
31570488
12.

Temporal efficacy of antimicrobials against aerobic bacteria isolated from equine endometritis: an Italian retrospective analysis (2010-2017).

Pisello L, Rampacci E, Stefanetti V, Beccati F, Hyatt DR, Coletti M, Passamonti F.

Vet Rec. 2019 Nov 16;185(19):598. doi: 10.1136/vr.105413. Epub 2019 Aug 13.

PMID:
31409748
13.

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.

Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM.

Am J Hematol. 2019 Sep;94(9):E239-E242. doi: 10.1002/ajh.25555. Epub 2019 Jun 22. No abstract available.

PMID:
31179561
14.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

15.

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).

Elli EM, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E, Maffioli M, Gardellini A, Carraro MC, D'Adda M, Polverelli N, Rossi M, Orofino N, Carrer A, Gambacorti-Passerini C, Antolini L, Passamonti F.

Br J Haematol. 2019 Sep;186(5):e123-e126. doi: 10.1111/bjh.15964. Epub 2019 May 20. No abstract available.

PMID:
31106402
16.

Stem cell transplant in MF: it's time to personalize.

Passamonti F.

Blood. 2019 May 16;133(20):2118-2120. doi: 10.1182/blood-2019-03-900860. No abstract available.

PMID:
31097535
17.

Emerging feline vector-borne pathogens in Italy.

Morganti G, Veronesi F, Stefanetti V, Di Muccio T, Fiorentino E, Diaferia M, Santoro A, Passamonti F, Gramiccia M.

Parasit Vectors. 2019 May 2;12(1):193. doi: 10.1186/s13071-019-3409-8.

18.

Equine Adipose-Derived Mesenchymal Stromal Cells Release Extracellular Vesicles Enclosing Different Subsets of Small RNAs.

Capomaccio S, Cappelli K, Bazzucchi C, Coletti M, Gialletti R, Moriconi F, Passamonti F, Pepe M, Petrini S, Mecocci S, Silvestrelli M, Pascucci L.

Stem Cells Int. 2019 Mar 18;2019:4957806. doi: 10.1155/2019/4957806. eCollection 2019.

19.

First molecular detection of ball python nidovirus in Italy - Short communication.

Rampacci E, Masi M, Origgi FC, Stefanetti V, Bottinelli M, Selleri P, Coletti M, Passamonti F.

Acta Vet Hung. 2019 Mar;67(1):127-134. doi: 10.1556/004.2019.014.

PMID:
30922084
20.

Developments in diagnosis and treatment of essential thrombocythemia.

Mora B, Passamonti F.

Expert Rev Hematol. 2019 Mar;12(3):159-171. doi: 10.1080/17474086.2019.1585239. Epub 2019 Mar 13.

PMID:
30793984
21.

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, Di Rocco A, Ferrari A, Farina L, Pirisi M, Piazza F, Loustaud-Ratti V, Arcari A, Marino D, Sica A, Goldaniga M, Rusconi C, Gentile M, Cencini E, Benanti F, Rumi MG, Ferretti VV, Grossi P, Gotti M, Sciarra R, Tisi MC, Cano I, Zuccaro V, Passamonti F, Arcaini L.

Oncologist. 2019 Aug;24(8):e720-e729. doi: 10.1634/theoncologist.2018-0331. Epub 2018 Dec 14.

22.

Retrospective Biomolecular Investigation of Coxiella burnetii and Leptospira spp. DNA in Cases of Abortion, Stillbirth and Neonatal Mortality in Dogs and Cats.

Stefanetti V, Compagnone A, Sordini C, Passamonti F, Rampacci E, Moscati L, Marenzoni ML.

Top Companion Anim Med. 2018 Dec;33(4):122-125. doi: 10.1053/j.tcam.2018.08.005. Epub 2018 Aug 20.

23.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

24.

Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.

Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.

Leukemia. 2018 Dec;32(12):2727-2728. doi: 10.1038/s41375-018-0259-x. Epub 2018 Sep 28. No abstract available.

PMID:
30267006
25.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F.

J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x.

26.

Exposure of Owned Dogs and Feeding Ticks to Spotted Fever Group Rickettsioses in Central Italy.

Stefanetti V, Morganti G, Veronesi F, Gavaudan S, Capelli G, Ravagnan S, Antognoni MT, Bianchi F, Passamonti F.

Vector Borne Zoonotic Dis. 2018 Dec;18(12):704-708. doi: 10.1089/vbz.2018.2303. Epub 2018 Aug 21.

PMID:
30129908
27.

In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Rampacci E, Marenzoni ML, Chiaradia E, Passamonti F, Ricci M, Pepe M, Coletti M, Giovagnoli S.

Sci Rep. 2018 Aug 14;8(1):12149. doi: 10.1038/s41598-018-30715-z.

28.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
29.

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.

Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28. No abstract available.

PMID:
29955128
30.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

31.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.

32.

Chronic myeloproliferative neoplasms in the elderly.

Maffioli M, Orlandi E, Passamonti F.

Eur J Intern Med. 2018 Dec;58:33-42. doi: 10.1016/j.ejim.2018.05.005. Epub 2018 May 22. Review.

PMID:
29793825
33.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
34.

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Passamonti F, Mora B, Barraco D, Maffioli M.

Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y. Review.

PMID:
29713873
35.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12.

PMID:
29650801
36.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

37.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

38.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

39.

Antimicrobial susceptibility survey on bacterial agents of canine and feline urinary tract infections: Weight of the empirical treatment.

Rampacci E, Bottinelli M, Stefanetti V, Hyatt DR, Sgariglia E, Coletti M, Passamonti F.

J Glob Antimicrob Resist. 2018 Jun;13:192-196. doi: 10.1016/j.jgar.2018.01.011. Epub 2018 Feb 3.

PMID:
29408407
40.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713
41.

Investigation of the antibiotic resistance and biofilm formation of Staphylococcus pseudintermedius strains isolated from canine pyoderma.

Stefanetti V, Bietta A, Pascucci L, Marenzoni ML, Coletti M, Franciosini MP, Passamonti F, Casagrande Proietti P.

Vet Ital. 2017 Dec 29;53(4):289-296. doi: 10.12834/VetIt.465.2275.6.

42.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
43.

Therapy of polycythemia vera: is it time to change?

Passamonti F, Maffioli M, Mora B.

Oncotarget. 2017 Nov 3;8(61):102759-102760. doi: 10.18632/oncotarget.22282. eCollection 2017 Nov 28. No abstract available.

44.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
45.

Pathology in Practice.

Lepri E, Beccati F, Miglio A, Passamonti F, Veronesi F, Mandara MT.

J Am Vet Med Assoc. 2017 Nov 15;251(10):1153-1156. doi: 10.2460/javma.251.10.1153. No abstract available.

PMID:
29099246
46.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
47.

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.

Maffioli M, Mora B, Passamonti F.

Clin Adv Hematol Oncol. 2017 Sep;15(9):700-707. Review.

PMID:
28949941
48.

DNA microarray assay and real-time PCR as useful tools for studying the respiratory tract Mycoplasma populations in young dairy calves.

Bottinelli M, Passamonti F, Rampacci E, Stefanetti V, Pochiero L, Coletti M, Rueca F, Hyatt DR, Schnee C.

J Med Microbiol. 2017 Sep;66(9):1342-1349. doi: 10.1099/jmm.0.000571. Epub 2017 Sep 4.

PMID:
28868997
49.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

50.

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.

Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.

Supplemental Content

Loading ...
Support Center